Press Releases and Events
PRESS RELEASES
Press Release | September 3, 2020
Press Release | August 7, 2020
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
READ MORE
Press Release | July 8, 2020
FDA Grants Crinetics Pharmaceuticals (CRNX) Orphan Drug Designation - Paltusotine for the Treatment of Acromegaly
READ MORE
Press Release | June 11, 2020
Crinetics Confirms Completion - Half of Enrolled Patients in Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
READ MORE
Press Release | May 8, 2020
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
READ MORE
Press Release | April 17, 2020
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
READ MORE
Press Release | April 15, 2020
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
READ MORE
Press Release | April 14, 2020
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
READ MORE
Press Release | April 6, 2020
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
